A pivotal clinical investigation spearheaded by the Garvan Institute of Medical Research has unveiled compelling evidence suggesting that metformin, a long-established and economically accessible medication primarily recognized for its efficacy in treating type 2 diabetes, may offer a substantial benefit to individuals diagnosed with type 1 diabetes by reducing their reliance on exogenous insulin. This discovery potentially heralds a novel and more manageable approach to navigating the complexities of this chronic autoimmune condition.
For an extended period, the medical community has explored the utility of prescribing metformin to certain individuals with type 1 diabetes, driven by the theoretical prospect of ameliorating insulin resistance. However, this practice has largely been substantiated by a limited body of empirical data. The recent findings from a meticulously designed, controlled clinical trial now provide robust confirmation that, while metformin does not demonstrably improve insulin resistance in the context of type 1 diabetes, it does facilitate a reduction in the total quantity of insulin required to maintain blood glucose levels within a healthy and stable physiological range.
Published in the esteemed scientific journal Nature Communications, this research illuminates an unexpected therapeutic advantage that could considerably alleviate the daily burdens and multifaceted challenges inherent in lifelong insulin therapy for individuals with type 1 diabetes.
The intricate landscape of managing type 1 diabetes presents a formidable daily undertaking for those affected. Type 1 diabetes, an autoimmune disorder affecting over 130,000 Australians, is characterized by the immune system’s erroneous targeting and destruction of the insulin-producing beta cells within the pancreas. Consequently, individuals diagnosed with this condition face a lifelong necessity of administering exogenous insulin to regulate their blood sugar levels and prevent life-threatening hyperglycemic events.
The management regimen for type 1 diabetes is characterized by its demanding nature, requiring individuals to make an estimated 180 distinct decisions each day pertaining to the meticulous monitoring of their blood glucose and the precise adjustment of their insulin dosages. This constant vigilance is essential for maintaining glycemic control and averting both acute complications, such as diabetic ketoacidosis, and the long-term sequelae associated with chronic hyperglycemia.
Over time, a significant subset of individuals with type 1 diabetes may develop insulin resistance, a state in which their bodies become less responsive to the action of insulin. This phenomenon necessitates escalating doses of insulin to achieve the same degree of glycemic control, thereby compounding the management challenges and potentially increasing the risk of adverse effects.
Dr. Jennifer Snaith, an endocrinologist and a co-lead investigator of the study, underscores the escalating concern surrounding insulin resistance in type 1 diabetes. She notes, "Insulin resistance is a growing problem in type 1 diabetes. Not only does it make regulating blood sugar levels difficult, but it is an underappreciated risk factor for heart disease, which is one of the biggest causes of health complications and deaths in those with type 1 diabetes." The link between insulin resistance and cardiovascular morbidity is a critical consideration in optimizing long-term health outcomes for this patient population.
In an effort to rigorously assess the potential benefits of metformin, researchers embarked on the first randomized controlled trial of its kind specifically designed for adults diagnosed with type 1 diabetes. This study, formally designated the Insulin Resistance in Type 1 Diabetes Managed with Metformin (INTIMET) study, was conceived to ascertain whether metformin could effectively mitigate insulin resistance within this demographic. Metformin, a widely prescribed medication for type 2 diabetes, is already being utilized off-label for approximately 13,000 Australians with type 1 diabetes, though its precise physiological effects in this population remained largely uncharacterized prior to this investigation.
Professor Jerry Greenfield elaborated on the study’s methodology: "We randomized 40 adults with long-term type 1 diabetes to take either metformin or a placebo for six months. We examined whether their insulin resistance changed over that time through a sophisticated and comprehensive research technique, called a clamp study, that allowed us to map insulin resistance in different parts of the body." The clamp study, a gold standard in metabolic research, involves precisely infusing glucose and insulin to maintain stable blood glucose levels while measuring the body’s response, thereby providing a detailed assessment of insulin sensitivity and resistance.
The study’s outcomes, however, deviated from the initial expectations regarding insulin resistance. The researchers observed no discernible improvement in insulin resistance and no statistically significant alterations in blood glucose levels among the participants who received metformin. This finding challenged the prevailing hypothesis that metformin’s primary benefit in type 1 diabetes would stem from enhanced insulin sensitivity.
Nevertheless, a singular and highly significant observation emerged from the trial: individuals who were administered metformin required approximately 12% less insulin compared to their counterparts in the placebo group to maintain stable blood glucose levels. This reduction in insulin dosage, while not attributable to improved insulin resistance, represents a clinically meaningful outcome for individuals managing type 1 diabetes.
Dr. Snaith articulated the significance of this unexpected finding: "Although we didn’t find changes to insulin resistance from the use of metformin, we did show that people taking it used around 12% less insulin than those on placebo. This is an important result. Insulin is a relatively old treatment which, while lifesaving, comes with significant mental and physical burden. This means that lowering the amount of insulin used is a priority for many people living with type 1 diabetes. We have shown that a very cheap, accessible medication may serve this purpose and this is very exciting." The daily burden of insulin injections, continuous glucose monitoring, and the psychological toll of managing a chronic condition can be substantial. A reduction in insulin needs, even if modest, could translate into improved quality of life and reduced financial strain.
In light of these intriguing results, the scientific team is now actively engaged in deciphering the underlying mechanisms by which metformin achieves this reduction in insulin requirements, particularly given its apparent lack of impact on insulin resistance. Professor Greenfield highlighted the enduring mystery surrounding metformin’s mechanism of action, stating: "Metformin has been available in various forms for around 100 years, but its mechanism of action remains unknown. We would have expected that the observed reductions in insulin dose induced by metformin in our study would be due to the body becoming more sensitive to insulin, that is, becoming less insulin resistant. But we have shown that is not the case. Our priority is now working out how metformin is achieving this effect."
A prominent hypothesis under investigation centers on the potential influence of metformin on the gut microbiome. Researchers are exploring the possibility that metformin may modulate the composition and function of the gut bacteria, thereby indirectly affecting the body’s metabolic processes, including glucose homeostasis. The intricate interplay between the gut microbiome and host metabolism has become a burgeoning area of scientific inquiry, with growing evidence implicating microbial communities in a wide range of physiological and pathological processes.
Dr. Snaith further elaborated on this avenue of research: "There is increasing evidence suggesting that metformin may act on the gut. This is why we are now investigating how metformin changes gut flora, also known as the microbiome, in people with type 1 diabetes. This has not been studied before in type 1 diabetes. We’re hoping this will provide clues on metformin’s mechanism of action, so that it can be more widely used in the management of type 1 diabetes." Understanding these novel mechanisms could pave the way for more targeted and personalized therapeutic strategies for type 1 diabetes management.
This groundbreaking research received crucial financial support from the Diabetes Australia Research Program, St Vincent’s Clinic Research Foundation, UNSW Cardiac Vascular and Metabolic Medicine Theme, the National Health and Medical Research Council, as well as generous contributions from Melissa and Jonathon Green, and Dr. Leslie and Mrs Ginny Green. The collaborative efforts of these entities underscore the significant investment in advancing diabetes research.
The research team comprises distinguished professionals, including Dr. Jennifer Snaith, an endocrinologist at St Vincent’s Hospital Sydney and a post-doctoral research scientist, who also serves as the Clinical Lead of the Australian Collaborative Towards Adjunctive Therapies in Type 1 Diabetes (ACT-T1D). Professor Jerry Greenfield, a faculty member at the Garvan Institute of Medical Research, holds the positions of Chair of ACT-T1D, Head of the Department of Diabetes and Endocrinology at St. Vincent’s Hospital, Sydney, and Head of the St. Vincent’s Health Care Campus within the Faculty of Medicine and Health at UNSW Sydney. Their collective expertise and dedication have been instrumental in driving this significant advancement in diabetes care.
About the Author
